Search PubMed⌕ Search

Biomedical subjects

Y Suda

Publications and source records attributed to Y Suda.

At least 145 records · Page 8Linked to original sources
PubMed1986

Chimeric potency of a mutator strain of mouse teratocarcinoma cells.

The developmental potential of a mutator strain Ara Cr (1.5)4 of mouse teratocarcinoma cells was examined by injecting these cells into host blastocysts. Analysis of developing embryos at 9.5 days of gestation showed the mutator strain gave chimeras at a rate comparable with that of the parent strain. However, most of these chimeric embryos with the mutator strain were abnormal, and the extent of abnormality seems to be related to the proportion of the mutator-derived cells in the embryos. When injected embryos were allowed to develop to 14.5 days, the number of developing embryos decreased, and only a few were chimeric in limited tissues. The results suggest that the mutator strain is lethal to early gestational development, and only those chimeras with limited colonization of the strain can develop normally beyond this stage.

Animals↗
PubMed1986

[Excretion of cis-diamminedichloro platinum (CDDP) into pancreatic juice and hepatic bile].

By means of pancreatic and biliary duct drainage in two pancreato-duodenectomized patients, excretion of CDDP into pancreatic and hepatic bile was studied. CDDP was infused at a dose of 50 mg/m2 for 40-60 min. Platinum was determined by the flameless atomic absorption spectrometric method. CDDP was excreted into pancreatic juice in the form of filterable platinum over a short duration and in a small amount. The excretion gradient into pancreatic juice was around 20%. Total output of CDDP in pancreatic juice was estimated to be 0.1% of administered platinum. Although no new observations on the urinary and biliary excretion of CDDP were obtained, it was noticed that platinum was excreted in filterable form in both urine and bile, and that the excretion gradients in each were approximately 300% and 35%, respectively, in the present study.

Bile↗
PubMed1986

[Chronic subdural hematoma secondary to metastasis of adenocarcinoma of the dura mater and skull--a case report].

A 72 year-old woman was hospitalized with the complaint of headache and nausea. Under the diagnosis of right chronic subdural hematoma, a small craniotomy was performed for the total removal of the hematoma. The patient died 14 days after the operation because of the complication of acute DIC. Histologically, metastasis of adenocarcinoma was detected in the dura mater and skull. Previously reported cases of subdural hematoma secondary to cancer were reviewed in the literature. It is considered that a coagulation defect such as DIC may play a significant role in the development of subdural hematoma. It is suggested that the chronic subdural hematoma in the present case was caused by chronic DIC due to metastasis of bone marrow, and that the patient deteriorated as a result of acute DIC triggered by the surgical therapy.

Adenocarcinoma↗
PubMed1985

[A case of advanced gastric cancer showing complete cure by immunochemotherapy with FT-207 and OK-432 confirmed by thorough histologic examination of total gastrectomy matter].

A 57-year-old woman was referred to our hospital because of epigastric tumor on Jan. 16, 1980. Two advanced gastric carcinomas were recognized in the antrum and the corpus by X-ray and endoscopic examinations. The biopsy diagnosis was poorly differentiated adenocarcinoma. She was treated with FT-207 suppositories and subcutaneous injection of OK-432 without operation because of a suspicion of ascites and Virchow's metastasis. After five months, the tumor of the corpus disappeared, and, after nine months, that of the antrum changed to a scarlike lesion. On July 30, 1981, total gastrectomy with extended nodal dissection was performed. Histological examination revealed complete absence of carcinoma cells in the stomach and regional lymph nodes.

Adenocarcinoma↗
PubMed1985

[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].

Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group. In the intermediate-dose MTX group, the drug was given at a dosage of 100 mg/m2 intravenously (i.v.) and followed 1 hour later by 5-FU at 800 mg/m2 i.v. (dripping for 1 hour); the drugs were recycled every 1 week. In the high-dose MTX group, the drug was administered at a dose of 1.5 g/m2 i.v. (dripping for 2 hours) and followed 1 hour later by 5-FU at 1.5 g/m2 i.v. (dripping for 2 hours); the drugs were recycled every 2-3 weeks. Average MTX concentrations in serum at the start of 5-FU administration were 1.69 X 10(-5) and 1.33 X 10(-4) mol/l/h in the intermediate and high-dose MTX groups, respectively. Six (50%) of 12 patients adequately treated with intermediate-dose MTX had a partial response (PR), and one (14.3%) of 7 evaluable patients treated with high-dose MTX had a PR. Major toxicity included diarrhea (33.3%) in the intermediate-dose MTX group and hair loss (71.4%) in the high-dose MTX group. Hematological toxicity was mild in MTX group: six (50%) of 12 patients had a granulocyte count nadir less than 1,000/microliters and one (8.3%) of 12 patients had a platelet count nadir less than 10(5)/microliters in the intermediate-dose MTX group. Five (71.4%) of 7 patients had a granulocyte nadir less than 1,000/microliters and two (28.6%) of 7 patients had a platelet count nadir less than 10(5)/microliters in the high-dose MTX group.

Adult↗
PubMed1985

[Failure to augment the tissue concentration of Adriamycin by simultaneous intra-arterial application of urokinase].

A previous study by the authors has made it clear that regional arterial infusion of Adriamycin (ADM) increases the drug concentration in the gastric tissue and the regional lymph nodes. In order to obtain further augmentation of the ADM concentration, simultaneous arterial infusion of ADM and Urokinase (UK), as a lysosome labilizer, was tried in the present study. ADM and UK were infused in three different ways through the left gastric artery on laparotomy, that is, a mixture of both in the first group, ADM followed by UK in the second group and ADM after UK in the third group. No augmentation of tissue ADM was obtained by any of these three methods and ADM concentration in gastric tumors, gastric wall and regional lymph nodes was rather lower than that using ADM only. A similar tendency was observed in the adjacent organs; liver, pancreas and spleen. Furthermore, the three-year survival rates of these groups were not statistically significant against the control group treated with ADM only.

Doxorubicin↗
PubMed1985

[Evaluation of absolute non-curative resection in colorectal carcinoma].

A total of 241 cases with colorectal carcinoma were treated surgically at our hospital in the past 8 years. Of these, the non-curative resection was performed in 62 cases (absolute non-curative resection in 54 and relative non-curative resection in 8). In this study 54 cases (27 colonic carcinoma and 27 rectal carcinoma) with absolute non-curative resection were evaluated from the aspect of pathologic findings and survival rate according to the non-curative factors (liver metastasis, peritoneal dissemination, lymph node metastasis and distant metastasis). Seventeen cases (63.0%) had two or more non-curative factors in the cases with colonic carcinoma and 21 cases (77.8%) one factor, especially liver metastasis, in the cases with rectal carcinoma. In the cases with rectal carcinoma, the invasion to the adjacent structures was recognized in 48.1%. The survival rates were correlated with the extent of the non-curative factors in the cases with absolute non-curative resection. However, longer survival would be expected, if the primary tumor could be resected, even in absolute non-curative resection for colorectal carcinoma.

Adenocarcinoma↗
PubMed1984

[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].

A total of thirteen patients with histologically-proved adenocarcinoma of stomach took part in this study at Saitama Cancer Center between July 1982 and September 1983; nine patients were considered evaluable. There were 7 male and 2 female patients with a median age of 52 yrs (range 42-75) and a median performance status of 3 (range 2-4). Patients were treated with a two drug combination of cis-diammine dichloroplatinum (II) and fluoropyrimidine derivatives (tegafur, cormobur ). Three out of 9 evaluable patients (33.3%) had a partial response which lasted 10 months. 6+ months, and 5+ months, respectively. The major toxic effect was a gastrointestinal symptom which was generally manageable. Myelosuppression was mild.

Adenocarcinoma↗